Paul Baverel

Paul Baverel, PhD, serves as Senior Director of Clinical Pharmacology at Molecular Partners, specializing in dosing optimization for T-cell engagers and radioligand therapies. With extensive experience in clinical pharmacology, pharmacometrics, and drug development, Paul previously held leadership roles at Roche, MedImmune, and Eli Lilly, managing teams and guiding decision-making processes across oncology and virology pipelines. Paul possesses a strong educational background with multiple degrees, including a PhD in Pharmacometrics from Uppsala University, and a Postgraduate Diploma in Entrepreneurship from Cambridge Judge Business School. Professional contributions include the regulatory approval of biologic projects and the development of innovative modeling strategies that have advanced drug candidates through various development phases.